Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 5/20 | 0.37 |
| ▸ | CES1 | P23141 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154820 | 0.89 | ALDH1A1 (0.39) | SMN1; SMN2MEN1KMT2ACES2CES1 | |
| SCHEMBL7508732 | 0.84 | NPC1 (0.36) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9339627 | 0.82 | ESR2 (0.43) | SMN1; SMN2CES2CES1CYP1A2ALDH1A1 | |
| SCHEMBL8548715 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2MEN1KMT2ARAB9ACES2 | |
| SCHEMBL8815350 | 0.80 | NR3C2 (0.40) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5781172 | 0.79 | MMP2 (0.38) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7833590 | 0.72 | ALDH1A1 (0.38) | SMN1; SMN2MEN1KMT2ACES2CES1 | |
| SCHEMBL7550562 | 0.71 | ALOX5 (0.41) | CES2CES1CYP1A2CA1CA2 | |
| SCHEMBL7087792 | 0.70 | CES2 (0.53) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7843105 | 0.70 | NPC1 (0.38) | MEN1KMT2ANPC1RAB9ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-0699192-B1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6090834-A | ANALGESICS; RHEUMATIC DISORDERS; SKIN DISORDERS; GASTROINTESTINAL DISORDERS | G.D. SEARLE & CO. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0825989-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5719163-A | ARTHRITIS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | SMN1; SMN2 3814/4885MEN1 4791/4885KMT2A 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.